GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PYC Therapeutics Ltd (ASX:PYC) » Definitions » Debt-to-Revenue

PYC Therapeutics (ASX:PYC) Debt-to-Revenue : N/A (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is PYC Therapeutics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

PYC Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.32 Mil. PYC Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.22 Mil. PYC Therapeutics's annualized Revenue for the quarter that ended in Dec. 2023 was A$0.00 Mil.


PYC Therapeutics Debt-to-Revenue Historical Data

The historical data trend for PYC Therapeutics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PYC Therapeutics Debt-to-Revenue Chart

PYC Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

PYC Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of PYC Therapeutics's Debt-to-Revenue

For the Biotechnology subindustry, PYC Therapeutics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PYC Therapeutics's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PYC Therapeutics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where PYC Therapeutics's Debt-to-Revenue falls into.



PYC Therapeutics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

PYC Therapeutics's Debt-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.178 + 0.138) / N/A
=N/A

PYC Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.324 + 0.22) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.


PYC Therapeutics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of PYC Therapeutics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


PYC Therapeutics (ASX:PYC) Business Description

Traded in Other Exchanges
N/A
Address
6 Verdun Street, Harry Perkins Institute of Medical Research, Nedlands, Perth, WA, AUS, 6009
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.

PYC Therapeutics (ASX:PYC) Headlines

No Headlines